ETFs positioned on Orion Oyj

Name YTD change Weight AuM
+11.81%-.--% 27,154 M€
+5.72%-.--% 49 M€
+6.59%-.--% 75 M€
+9.19%-.--% 122 M€
+11.85%-.--% 5,871 M€
+1.14%-.--% 51 M€
+8.94%-.--% 66 M€
+8.75%-.--% 274 M€
+10.54%-.--% 67 M€
+9.52%-.--% 3,469 M€
+7.69%-.--% 1,193 M€
+13.01%2.1% 114 M€
+7.75%2% 26 M€
+2.41%1.25% 48 M€
+4.80%1.25% 57 M€
+4.73%1.14% 82 M€
+5.28%1.14% 37 M€
+7.96%1.12% 172 M€
+10.12%1.01% 682 M€
+14.54%0.78% 408 M€
+13.51%0.71% 646 M€
+11.58%0.69% 160 M€
+9.59%0.67% 140 M€
+12.37%0.65% 788 M€
+11.77%0.65% 256 M€
+10.24%0.64% 103 M€
+7.37%0.63% 125 M€
+9.91%0.62% 69 M€
+9.83%0.61% 349 M€
+13.12%0.61% 168 M€
+5.80%0.59% 1,203 M€
+9.64%0.57% 11 M€
+0.53%0.57% 730 M€
+12.30%0.56% 53 M€
-3.93%0.56% 391 M€
+9.15%0.55% 6 M€
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!